Results: An animal model using glioma cells transfected with a luciferase reporter has been developed, and after conventional GBM therapy, this animal model can be evaluated with posttreatment bioluminescence imaging and various MR tumor imaging modalities. Conclusions: Posttreatment radiographic changes ...
The summarized reasons for the lack of effective regimens in recurrent GBM were listed in Introduction. The intrinsic resistance of tumor cells; The molecular heterogeneity; The reduced concentration of effective treatment due to the blood-brain-tumor barrier; The difficult prediction of clinical efficac...
Among these patients, three were further pursued to have the organoids derived from their tumor tissues tested for the sensitivity to different therapeutic drugs in parallel to their clinical care. Our results showed that the therapeutic effects observed by the organoid models were consistent to the...
PDGF-A as well as PDGFRα and β are induced[199]. Inhibition of PDGF receptor signaling was found to decrease cell migrationin vitroand tumor growthin vivo, in a β-catenin-dependent manner, indicating an important role for PDGF signaling in hepatocyte tumor progression...
Programmed death-ligand 1Recurrent glioblastomaThis study was designed to analyze the results of recurrent glioblastoma (GBM) treatment, investigate the changes in molecular expression on paired primary and recurrent tumor specimens of GBM, and evaluate the effect of these changes on patient survival.#...
In a study conducted on 30 patients with a history of treatment for GBM (1,5 T, pASL), ASL nCBF values were determined to be higher than DSC nCBV values. No difference was observed between patients with and without tumor recurrence. Researchers have suggested that since the single-PLD ...
Over time, it is the tumor heterogeneity of GBM and the ability of the cancer stem cells to evolve in response treatment that renders the cancer refractory to conventional treatment. Therefore, research has increasingly focused on treatment that incorporates knowledge of GBM molecular biology to ...
represents what the team describe as a major roadblock that contributes to such a “dismal prognosis.” And while the standard of care for primary treatment has been established, they continued, “… recurrent GBM remains therapeutically unresolved due to the complexity of tumor heterogeneity an...
You have had surgery to remove as much of the tumor as possible Recurrent GBM If your tumor has come back, Optune Gio can be used alone as an alternative to standard medical therapy if: You have tried surgery and radiation and they did not work or are no longer working AND You have tr...
The inherent characteristics of glioblastoma multiforme (GBM), including tumoral heterogeneity and invasive capacity, combined with the presence of the blood-brain tumor barrier (BBTB), present challenges in developing effective treatment for GBM. Especially, the margins of GBM, where GBM cells ...